These results reveal a novel mechanism that IL4/IL4Ra signaling impacts the proliferative stage of preosteoclasts and therefore Ravoxertinib could be a potential therapeutic in the treatment of patients with bone metastasis from CRC. Here, IL4 is linked to colorectal carcinoma.